VP of Clinical Operations transitions to consultant role after FDA setback
Summary
Grace Therapeutics' Vice President of Clinical Operations, Carrie D'Andrea, is stepping down from her executive role but will continue to provide clinical development and NDA-related consulting services for 12 months.
Key Events
-
Executive Departure
Carrie D'Andrea, Vice President of Clinical Operations, will cease serving in her executive role effective June 5, 2026.
-
Transition to Consulting Role
Ms. D'Andrea has entered into a 12-month Consulting Agreement with the company to provide clinical development and NDA-related services at a fee of $250 per hour.
-
Continued Option Vesting
Her stock option awards will continue to vest and remain exercisable during the term of the Consulting Agreement.
Analysis
This change in leadership for a critical function like clinical operations is notable, especially following the recent FDA Complete Response Letter for GTx-104. While Ms. D'Andrea is departing her executive role, the company has secured her expertise for another year through a consulting agreement, which is a pragmatic move to maintain continuity during a challenging regulatory period. The continued vesting of her stock options incentivizes her ongoing engagement.
At the time of this filing, GRCE was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.6M. The 52-week trading range was $1.79 to $5.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.